%0 Journal Article %A Roberto Littera %A Maurizio Melis %T How many relevant SARS-CoV-2 variants might we expect in the future? %D 2021 %R 10.1101/2021.11.17.21266463 %J medRxiv %P 2021.11.17.21266463 %X Objectives The emergence of new SARS-CoV-2 variants is a major challenge in the management of Covid-19 pandemic. A crucial issue is to quantify the number of variants which may represent a potential risk for public health in the future.Methods We fitted the data on the most relevant SARS-CoV-2 variants recorded by the World Health Organization (WHO). The function exploited for the fit is related to the total number of infected subjects in the world since the start of the epidemic.Results We found that the number of relevant SARS-CoV-2 variants up to November 2021 was about 44. Moreover, the number of new relevant variants per ten million cases turned out to be 1.64 in November 2021, slightly decreased in comparison to the value of 2.29 in March 2020.Conclusions Our simple mathematical model can evaluate the number of relevant SARS-CoV-2 variants as the cumulative number of cases increase worldwide and may represent a useful tool in planning strategies to effectively contrast the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://www.who.int/en/activities/tracking-SARS-CoV-2-variantsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available online at https://www.who.int/en/activities/tracking-SARS-CoV-2-variants %U https://www.medrxiv.org/content/medrxiv/early/2021/11/21/2021.11.17.21266463.full.pdf